# Interferon Alpha Lozenges Plus Oseltamivir for Influenza Treatment

> **NCT01146535** · PHASE2 · COMPLETED · sponsor: **Ainos, Inc. (f/k/a Amarillo Biosciences Inc.** · enrollment: 40 (actual)

## Conditions studied

- Influenza A Virus Infection

## Interventions

- **DRUG:** Interferon-alpha
- **DRUG:** Oseltamivir
- **OTHER:** maltose

## Key facts

- **NCT ID:** NCT01146535
- **Lead sponsor:** Ainos, Inc. (f/k/a Amarillo Biosciences Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01
- **Primary completion:** 2012-12
- **Final completion:** 2012-12
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2013-08-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01146535

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01146535, "Interferon Alpha Lozenges Plus Oseltamivir for Influenza Treatment". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT01146535. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*